<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03018444</url>
  </required_header>
  <id_info>
    <org_study_id>H-16034243</org_study_id>
    <nct_id>NCT03018444</nct_id>
  </id_info>
  <brief_title>The Effect of HMG-CoA Reductase Inhibition on Postprandial GLP-1 Secretion</brief_title>
  <official_title>The Effect of HMG-CoA Reductase Inhibition on Postprandial GLP-1 Secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <brief_summary>
    <textblock>
      The primary objective of the present study is to evaluate the effect of HMG-CoA reductase
      inhibition during 14 days on the postprandial plasma GLP-1 response in healthy individuals.
      Secondary objectives include the evaluation of HMG-CoA reductase inhibition on postprandial
      glucose tolerance, gallbladder emptying, gastric emptying, plasma responses of lipids, bile
      acids and pancreatic and enteric hormones known to influence glucose metabolism and appetite,
      and faecal content of bile acids and gut microbiota composition.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial GLP-1 secretion</measure>
    <time_frame>240 min</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postprandial Bile Acid Composition</measure>
    <time_frame>240 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial total plasma Bile Acid</measure>
    <time_frame>240 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Glucose Tolerance</measure>
    <time_frame>240 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial plasma lipid response</measure>
    <time_frame>240 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial GIP secretion</measure>
    <time_frame>240 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enteric hormones known to influence glucose metabolism</measure>
    <time_frame>240 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gallbladder emptying</measure>
    <time_frame>240 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Faecal content of bile acid</measure>
    <time_frame>One sample collected on day 12 or 13 of the intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota composition</measure>
    <time_frame>One sample collected on day 12 or 13 of the intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying</measure>
    <time_frame>240 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting Energy Expenditure</measure>
    <time_frame>At time -20 min, +60 min and +220 min</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Hydroxymethylglutaryl-CoA Reductase Inhibitors</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 weeks treatment with Atorvastatin (1st week 40 mg once daily on day, 2nd week 80 mg (2x40mg) once daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 weeks treatment with placebo tablets of comparable sizes and color to the Atorvastatin tablets (1st week one tablet once daily, 2nd week two tablets once daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin tablet</description>
    <arm_group_label>Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) &gt;18.5 kg/m2 and &lt;35 kg/m2

          -  Caucasian ethnicity

          -  Normal haemoglobin

          -  Glycated haemoglobin (HbA1c) &lt;43 mmol/mol

          -  Fasting plasma glucose &lt;6 mmol/l

          -  Informed and written consent

        Exclusion Criteria:

          -  Diabetes

          -  First-degree relatives with diabetes (both type 1 diabetes and type 2 diabetes)

          -  Liver disease (serum alanine aminotransferase (ALAT) and/or serum aspartate
             aminotransferase (ASAT) &gt;2 times normal values) or history of hepatobiliary disorder

          -  Gastrointestinal disease, previous intestinal resection, cholecystectomy or any major
             intra-abdominal surgery

          -  Reduced kidney function or nephropathy (estimated glomerular filtration rate (eGFR)
             &lt;60 ml/min/1.73 m2 (based on serum creatinine) and/or albuminuria

          -  Taking any kind of medicine on a regular basis

          -  Intake of antibiotics two months prior to study

          -  Active or recent malignant disease

          -  Any treatment or condition requiring acute or sub-acute medical or surgical
             intervention

          -  Any condition considered incompatible with participation by the investigators

          -  If the subjects receive any antibiotic treatment while included in the study they will
             be excluded
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip K. Knop, Professor MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Medicine, University of Copenhagen, Gentofte Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital, Gentofte, Copenhagen</name>
      <address>
        <city>Hellerup</city>
        <state>Region Hovedstaden</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2017</study_first_submitted>
  <study_first_submitted_qc>January 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2017</study_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Filip Krag Knop</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

